Nephrologische Therapie der schweren Herzinsuffizienz
Tóm tắt
Từ khóa
Tài liệu tham khảo
Hatamizadeh P et al (2013) Cardiorenal syndrome: pathophysiology and potential targets for clinical management. Nat Rev Nephrol 9(2):99–111
Schwenger V, Remppis AB (2012) Renal replacement therapy for refractory heart failure. Internist (Berl) 53(7):823–832
Neumann T et al (2009) Heart failure: the commonest reason for hospitalization in Germany—medical and economic perspectives. Dtsch Arztebl Int 106(16):269–275
Smith GL et al (2006) Renal impairment and outcomes in heart failure: systematic review and meta-analysis. J Am Coll Cardiol 47(10):1987–1996
Schwenger V et al (2014) Dialysis and ultrafiltration therapy in patients with cardio-renal syndrome: recommendations of the working group “heart-kidney” of the German Cardiac Society and the German Society of Nephrology. Dtsch Med Wochenschr 139(7):e1–8
Forman DE et al (2004) Incidence, predictors at admission, and impact of worsening renal function among patients hospitalized with heart failure. J Am Coll Cardiol 43(1):61–67
Heywood JT et al (2007) High prevalence of renal dysfunction and its impact on outcome in 118,465 patients hospitalized with acute decompensated heart failure: a report from the ADHERE database. J Card Fail 13(6):422–430
Schlieper G et al (2017) Anticoagulation in patients with chronic kidney disease: recommendations from the working group “Heart-Kidney” of the German Cardiac Society and the German Society of Nephrology. Internist (Berl) 58(5):512–521
Group SR et al (2015) A randomized trial of intensive versus standard blood-pressure control. N Engl J Med 373(22):2103–2116
Ponikowski P et al (2016) ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 37(27):2129–2200
Swedberg K et al (1990) Effects of enalapril and neuroendocrine activation on prognosis in severe congestive heart failure (follow-up of the CONSENSUS trial). CONSENSUS Trial Study Group. Am J Cardiol 66(11):40D–44D (discussion 44D–45D)
Epstein M et al (2015) Evaluation of the treatment gap between clinical guidelines and the utilization of renin-angiotensin-aldosterone system inhibitors. Am J Manag Care 21(11 Suppl):S212–20
Mann JF et al (2008) Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet 372(9638):547–553
Vardeny O et al (2012) Influence of baseline and worsening renal function on efficacy of spironolactone in patients with severe heart failure: insights from RALES (Randomized Aldactone Evaluation Study). J Am Coll Cardiol 60(20):2082–2089
McMurray JJ et al (2014) Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med 371(11):993–1004
Hughes-Austin JM et al (2017) The relation of serum potassium concentration with cardiovascular events and mortality in community-living individuals. Clin J Am Soc Nephrol 12(2):245–252
Schrier RW, Abraham WT (1999) Hormones and hemodynamics in heart failure. N Engl J Med 341(8):577–585
Block GA et al (2004) Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N Engl J Med 350(15):1516–1525
Simpson RU, Hershey SH, Nibbelink KA (2007) Characterization of heart size and blood pressure in the vitamin D receptor knockout mouse. J Steroid Biochem Mol Biol 103(3):521–524
Giovannucci E et al (2008) 25-hydroxyvitamin D and risk of myocardial infarction in men: a prospective study. Arch Intern Med 168(11):1174–1180
Lee JH et al (2008) Vitamin D deficiency an important, common, and easily treatable cardiovascular risk factor? J Am Coll Cardiol 52(24):1949–1956
Gutierrez OM et al (2008) Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med 359(6):584–592
Parker BD et al (2010) The associations of fibroblast growth factor 23 and uncarboxylated matrix Gla protein with mortality in coronary artery disease: the Heart and Soul Study. Ann Intern Med 152(10):640–648
Brandenburg VM et al (2014) Fibroblast growth factor 23 (FGF23) and mortality: the Ludwigshafen Risk and Cardiovascular Health Study. Atherosclerosis 237(1):53–59
Costanzo MR et al (2007) Ultrafiltration versus intravenous diuretics for patients hospitalized for acute decompensated heart failure. J Am Coll Cardiol 49(6):675–683
Costanzo MR et al (2016) Aquapheresis versus intravenous diuretics and hospitalizations for heart failure. Jacc Heart Fail 4(2):95–105
Bart BA et al (2012) Ultrafiltration in decompensated heart failure with cardiorenal syndrome. N Engl J Med 367(24):2296–2304
Frohlich H et al (2015) Peritoneal ultrafiltration in end-stage chronic heart failure. Clin Kidney J 8(2):219–225
Nunez J et al (2012) Continuous ambulatory peritoneal dialysis as a therapeutic alternative in patients with advanced congestive heart failure. Eur J Heart Fail 14(5):540–548
Sanchez JE et al (2010) Efficacy of peritoneal ultrafiltration in the treatment of refractory congestive heart failure. Nephrol Dial Transplant 25(2):605–610
Schwenger V (2017) Ultrafiltrationsverfahren bei Patienten mit kardiorenalem Syndrom. Nephro News 19(4/17):1–8